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For transport logistical reasons and for the decoupling of DS and DP shelf-life, most Biologics Bulk Drug 
Substances (BDS) are frozen and thawed before further processing. There are contradictory reports and 
publications on the influence of freezing processes - sometimes ultra-fast freezing is worse in terms of increased 
aggregate formation, sometimes slow freezing is inferior. Effects may only be visible upon subsequent long time 
storage (1, 2). The influence of the thawing process is usually neglected in the considerations and 
investigations, although here also protein can be damaged.  
 
Case studies reported in the presentation on various therapeutic proteins show that slow and apparently mild 
thawing at low temperatures can lead to gelation or precipitation due to protein-protein interactions. Following 
CFD simulations, we have changed the design of the existing blast freezers and also added fast blast thawing 
(fig.1). The presentation will introduce experiences with this new blast-freezer-thawer as well as with 
representative freeze-thaw downscale models applied to formulations of therapeutic proteins. It could be nicely 
demonstrated that cryo-concentration of a monoclonal antibody and of the buffer agent had the same pattern in 
the downscale model and in the 2 L at scale bottle (fig. 2). Techniques such as micro CT for studying ice 
structures and the distribution of formulation components in ice are also presented. 
 
               
Figure 1: Novel Blast Freezer Thawer 
   
Figure 2: Cryo-concentration factor of mAb in a  
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AIN 457 in 2 L PharmaTainer bottle
